Crystalline forms of pyridazinone TRPC inhibitors

Abstract

To provide TRPC1 ion channels useful in the treatment of kidney disease, TRPC4 ion channels, and methods of preparing crystalline forms of compounds useful as inhibitors of TRPC5 ion channels.SOLUTION: Provided are methods of preparing crystalline Form A of 4-chloro-5 - (4 - (4-fluoro-2 - (trifluoromethyl) phenoxy-5, 8-dihydropyrido [3, 4-d] pyrimidin-7 (6H) - yl) pyridazin-3 (2H) - one.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Related Applications This application claims the benefit of priority to International Application No. PCT / CN19 / 81985, filed April 10, 2019.

[0002] The present invention relates to crystalline polymorphs of Compound 100, pharmaceutical compositions containing the crystalline polymorphs, and methods of preparing pharmaceutical compositions using the crystalline polymorphs. [Background technology]

[0003] Proteinuria is a condition in which excessive amounts of blood protein leak into the urine. Proteinuria can progress from a loss of 30 mg of protein in the urine per 24 hours (called microalbuminuria) to a loss of more than 300 mg / day (called macroalbuminuria), and then reach levels of more than 3.5 grams per 24 hours, or 25 times the normal amount. Proteinuria occurs when the kidney's glomeruli malfunction, causing fluid accumulation (edema) in the body. Long-term protein leakage has been shown to lead to kidney failure. Nephrotic syndrome (NS) accounts for approximately 12% of end-stage renal disease cases and accounts for an annual cost of more than $3 billion in the United States. Approximately 5 per 100,000 children are diagnosed with NS each year, and 15 per 100,000 children currently suffer from NS. Even in patients who respond positively to treatment, recurrence is extremely common. While 90% of children with NS respond to treatment, an estimated 75% experience recurrence. There is a need for more effective methods of treating or reducing the risk of developing kidney disease (eg, proteinuria).

[0004] Mammalian TRP channel proteins form six-transmembrane, cation-permeable channels that can be classified into six subfamilies (TRPC, TRPV, TRPM, TRPA, TRPP, and TRPML) based on amino acid sequence homology. Recent research on TRP channels has demonstrated that they are involved in many fundamental cellular functions and likely play an important role in the pathophysiology of many diseases. Many TRPs are expressed along different parts of the nephron in the kidney, and increasing evidence suggests that these channels are involved in inherited as well as acquired kidney disorders. TRPC6, TRPM6, and TRPP2 are thought to be involved in hereditary focal segmental glomerulosclerosis (FSGS), hypomagnesemia with secondary hypocalcemia (HSH), and polycystic kidney disease (PKD), respectively. TRPC5 is also involved in FSGS and diabetic nephropathy (J Clin Invest. 2013 Dec 2; 123(12):5298-5309.10.1172 / JCI71165, Zhou et al., Science 358, 1332-1336(2017)).

[0005] TRPC5 has also been reported to contribute to the mechanisms underlying the regulation of innate fear responses (J Neurosci. 2014 Mar 5;34(10):3653-3667).

[0006] Therefore, there is a need for additional inhibitors of TRPC5. Summary of the Invention

[0007] In some embodiments, the present invention is directed to a crystalline form of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one selected from the following: Form A (anhydrous, characterized by powder X-ray diffraction peaks located at 2Θ angles of 4.43±0.2°, 11.69±0.2°, 17.75±0.2°, and 27.58±0.2°); Form H (anhydrous, characterized by powder X-ray diffraction peaks located at 2Θ angles of 13.79±0.2°, 23.61±0.2°, and 27.10±0.2°); Form E (a hydrate characterized by powder X-ray diffraction peaks at 2Θ angles of 11.71±0.2°, 15.24±0.2°, 24.79±0.2°, and 26.15±0.2°), or Form G (a hydrate characterized by powder X-ray diffraction peaks located at 2Θ angles = 15.34 ± 0.2°, 24.58 ± 0.2°, and 25.86 ± 0.2°).

[0008] In some embodiments, the present invention is directed to a crystalline form of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one additionally selected from the following: Form B (anhydrous and characterized by powder X-ray diffraction peaks located at 2Θ angles of 4.40±0.2°, 17.48±0.2°, 17.72±0.2°, and 27.49±0.2°), or Form C (a hydrate characterized by powder X-ray diffraction peaks located at 2Θ angles = 4.42 ± 0.2°, 8.83 ± 0.2°, 13.27 ± 0.2°, and 17.72 ± 0.2°).

[0009] In some embodiments, the present invention is directed to pharmaceutical compositions comprising crystalline form A.

[0010] In some embodiments, the present invention is directed to pharmaceutical compositions comprising crystalline form H.

[0011] In some embodiments, the present invention is directed to pharmaceutical compositions comprising crystalline form E.

[0012] In some embodiments, the present invention is directed to pharmaceutical compositions comprising crystalline form G.

[0013] In some embodiments, the present invention is directed to pharmaceutical compositions comprising crystalline form B.

[0014] In some embodiments, the present invention is directed to pharmaceutical compositions comprising crystalline form C.

[0015] In some embodiments, the present invention is directed to a method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, the method comprising combining a sample of crystalline Form A with a pharmaceutically acceptable carrier.

[0016] In some aspects, the present invention is directed to a method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, comprising: a. dissolving crystalline form A in a solvent to form a solution; b. preparing a pharmaceutical composition from the solution; Includes.

[0017] In some embodiments, the present invention is directed to a method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, the method comprising combining a sample of crystalline form H with a pharmaceutically acceptable carrier.

[0018] In some aspects, the present invention is directed to a method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, comprising: a. dissolving crystalline form H in a solvent to form a solution; b. preparing a pharmaceutical composition from the solution; Includes:

[0019] In some embodiments, the present invention is directed to a method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, the method comprising combining a sample of crystalline form E with a pharmaceutically acceptable carrier.

[0020] In some aspects, the present invention is directed to a method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, comprising: a. dissolving crystalline form E in a solvent to form a solution; b. preparing a pharmaceutical composition from the solution; Includes:

[0021] In some embodiments, the present invention is directed to a method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, the method comprising combining a sample of crystalline form G with a pharmaceutically acceptable carrier.

[0022] In some aspects, the present invention is directed to a method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, comprising: a. dissolving crystalline form G in a solvent to form a solution; b. preparing a pharmaceutical composition from the solution; Includes:

[0023] In some embodiments, the present invention is directed to a method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, the method comprising combining a sample of crystalline form B with a pharmaceutically acceptable carrier.

[0024] In some aspects, the present invention is directed to a method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, comprising: a. dissolving crystalline form B in a solvent to form a solution; b. preparing a pharmaceutical composition from the solution; Includes.

[0025] In some embodiments, the present invention is directed to a method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, the method comprising combining a sample of crystalline form C with a pharmaceutically acceptable carrier.

[0026] In some aspects, the present invention is directed to a method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, the method comprising the steps of: a. dissolving crystalline Form C in a solvent to form a solution; and b. preparing a pharmaceutical composition from the solution.

[0027] In some embodiments, the present invention is directed to methods for inhibiting one or more of the TRPC1 ion channel, the TRPC4 ion channel, and the TRPC5 ion channel, or any combination of tetrameric ion channels comprising TRPC1, TRPC4, and TRPC5, in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a crystalline form of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one. In some aspects of these embodiments, the ion channel is in a heterotetrameric form, which comprises one or more TRPC1 ion channels in combination with one or more TRPC4 and / or TRPC5 ion channels. In some aspects of these embodiments, the ion channel is in a heterotetrameric form, which heterotetrameric form comprises one or more TRPC4 ion channels and one or more TRPC5 ion channels.

[0028] In some aspects, the present invention is directed to a method of treating a kidney disease or nephropathy associated with a condition or disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one.

[0029] In some embodiments, the present invention is directed to a method for preparing crystalline form A, the method comprising: a. dissolving an amount of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in an amount of DMSO:ethanol (2:1 (v / v)) at room temperature to form a supersaturated solution; b. adding a sufficient amount of ethanol:HO (1:1 (v / v)) to the solution of step a to precipitate 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one; c. isolating the precipitated material from step b to obtain crystalline form A; Includes.

[0030] In some embodiments, the present invention is directed to a method for preparing crystalline form A, the method comprising: a. dissolving an amount of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in an amount of DMSO:ethanol (2:1 (v / v)) at room temperature to form a supersaturated solution; b. adding an amount of ethanol:HO (1:1 (v / v)) and seed crystals of crystalline form A to the solution of step a to precipitate 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one; c. isolating the precipitated material from step b to obtain crystalline form A; Includes.

[0031] In some embodiments, the present invention is directed to a method for preparing crystalline form H, the method comprising: a. suspending 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in isopropyl alcohol:isopropyl acetate (1:1 (v / v)); b. heating the suspension of step a to a temperature of 45°C to 55°C with stirring for at least 24 hours; c. isolating the insoluble material resulting from step b to obtain crystalline form H; Includes:

[0032] In some embodiments, the present invention is directed to a method for preparing crystalline form H, the method comprising: a. dissolving 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in DMSO:isopropyl alcohol (2:1 (v / v)) at a temperature of 45°C to 55°C; b. filtering the solution from step a through a PTFE membrane with a pore size of 0.45 microns; c. adding (i) isopropyl alcohol in an amount of 30-50% of the amount of isopropyl alcohol used in step a, and (ii) crystalline form H to the filtrate obtained from step b, and stirring at a temperature of 45°C to 55°C for at least 5 minutes; d. adding isopropyl alcohol:HO (1:1 (v / v)) to the solution resulting from step c over a period of at least 4 hours with stirring and maintaining the temperature at 45°C to 55°C to obtain a suspension of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, wherein the amount of isopropyl alcohol added in steps c and d is approximately equal to the amount of isopropyl alcohol added in step a; e. maintaining the suspension from step d at a temperature of 45°C to 55°C without stirring for at least 2 hours; f. isolating the precipitated material from step e to obtain crystalline form H; Includes:

[0033] In some embodiments, the present invention is directed to a method for preparing crystalline form H, the method comprising: a. dissolving 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in DMSO at a temperature of 65° C. to 75° C.; b. filtering the solution from step a through a PTFE membrane with a pore size of 0.45 microns; c. adding to the filtrate obtained from step b: (i) isopropyl alcohol:HO (1:1 (v / v)) in an amount that is about 10% of the volume of DMSO used in step A, and (ii) crystalline form H; d. adding additional isopropyl alcohol:HO (1:1 (v / v)) to the filtrate from step c with stirring over a period of at least 5 hours while maintaining the temperature at 65°C to 75°C to obtain a suspension of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, wherein the total volume of isopropyl alcohol added in step c and step d is about half the volume of DMSO used in step a; e. cooling the suspension of step d to room temperature while stirring for at least 2 hours; f. maintaining the suspension of step e at room temperature without stirring for at least an additional 45 minutes; g. isolating the precipitated material from step f to obtain crystalline form H; Includes:

[0034] In some embodiments, the present invention is directed to a method of forming crystalline form E, the method comprising: a. suspending 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in DMF / HO (1:9 (v / v)) at room temperature to form a slurry; b. vacuum drying the suspension; Includes:

[0035] In some embodiments, the present invention is directed to a method of forming crystalline form G, the method comprising: a. 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, w suspending the compound in a solvent having a viscosity of 0.8 or greater at room temperature to form a slurry; b. vacuum drying the suspension; Includes:

[0036] The purpose of providing the drawings is to illustrate, not to limit. [Brief explanation of the drawings]

[0037] [Figure 1A] 1 shows an experimental XRPD pattern of crystalline form A of Compound 100. [Figure 1B] 1 shows experimental thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) data for crystalline form A of Compound 100. [Figure 2A] 1 shows an experimental XRPD pattern of crystalline form H of compound 100. [Figure 2B] 1 shows experimental differential scanning calorimetry (DSC) data for crystalline form H of compound 100 obtained by crystallization in a DMSO / IPA / H2O system. [Figure 2C] 1 shows experimental TGA and DSC data for crystalline form H of Compound 100 obtained by slurrying Compound 100 in IPA / IPAc (1:1 (v / v)) at 50° C. [Figure 3A] 1 shows an experimental XRPD pattern of crystalline form E of compound 100. [Figure 3B] 1 shows experimental TGA and DSC data for crystalline form E of Compound 100. [Figure 4A] 1 shows an experimental XRPD pattern of crystalline form G of Compound 100. [Figure 4B] 1 shows experimental TGA and DSC data for crystalline form G of compound 100. [Figure 5A] 1 shows an experimental XRPD pattern of crystalline form B of Compound 100. [Figure 5B] 1 shows experimental TGA and DSC data for crystalline form B of Compound 100. [Figure 6A] 1 shows an experimental XRPD pattern of crystalline form C of Compound 100. [Figure 6B] 1 shows experimental TGA and DSC data for crystalline form C of Compound 100. DETAILED DESCRIPTION OF THE INVENTION

[0038] The present invention provides compound 100

[0039] [ka] Compound 100 is an inhibitor of TRPC1, TRPC4, and TRPC5, which is described in WO20 / 061162, US2020 / 0102301, U.S. Patent Application Nos. 16 / 575,161, filed September 18, 2019, 62 / 732,728, filed September 18, 2018, and 62 / 780,553, filed December 17, 2019, all of which are incorporated herein by reference.

[0040] Crystalline forms of Compound 100 can be used to modulate / improve the physicochemical properties of this compound, including, but not limited to, solid state properties (e.g., crystallinity, hygroscopicity, melting point, or hydration), pharmaceutical properties (e.g., solubility / dissolution rate, stability, or compatibility), and crystallization characteristics (e.g., purity, yield, or morphology).

[0041] In one aspect, the invention features crystalline Form A of Compound 100, having characteristic peaks in an X-ray powder diffraction (XRPD) pattern substantially similar to FIG. 1A.

[0042] In another aspect, the invention features crystalline Form A of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at the 2-theta values ​​(°2θ) shown in Table 1.

[0043] The relative intensities and 2-theta values ​​of each peak in Tables 1, 2, 3, and 4, and Figures 1A, 2A, 3A, and 4A, may change or shift under certain conditions, even if the crystalline form is the same. One of ordinary skill in the art would readily be able to determine whether a given crystalline form is the same crystalline form as that set forth in one of Figures 1A, 2A, 3A, and 4A or Tables 1, 2, 3, and 4 by comparing their XRPD data. As described herein, an XRPD dataset is "substantially similar" to another XRPD dataset if one or more of the peaks in one dataset are located within ±0.2° of the 2-theta value of the corresponding peak in the other dataset.

[0044] In yet another aspect, the invention features crystalline Form A of Compound 100 having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at two-theta values ​​(°2θ) of 4.43±0.2°, 11.69±0.2°, 17.75±0.2°, and 27.58±0.2°. In some embodiments, the characteristic peaks shown are the highest peaks in the XRPD pattern.

[0045] In yet another aspect, the present invention provides 2 theta values ​​(°2θ) = 4.43 ± 0.2°, 8.80 ± 0.2°, 9.17 ± 0.2°, 11.69 ± 0.2°, 12.27 ± 0.2°, 13.28 ± 0.2°, 14.24 ± 0.2°, 14.67 ± 0.2°, 15.96 ± 0.2°, 16.93 ± 0.2°, 17.75 ± 0.2°, 19. Crystalline Form A of Compound 100 is characterized as having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 64±0.2°, 20.98±0.2°, 22.23±0.2°, 22.71±0.2°, 24.19±0.2°, 25.55±0.2°, 27.58±0.2°, 27.95±0.2°, and 30.32±0.2°.

[0046] In yet another aspect, the invention features crystalline Form A of Compound 100, characterized by a differential scanning calorimetry pattern with an extrapolated onset temperature between 237±2° C. and 256±2° C. In some embodiments, the invention features crystalline Form A of Compound 100, characterized by a differential scanning calorimetry pattern with extrapolated onset temperatures at 236.4±1° C., 243.5±1° C., and 256.3±1° C.

[0047] In yet another aspect, the invention features crystalline form H of Compound 100, having characteristic peaks in an X-ray powder diffraction (XRPD) pattern substantially similar to Figure 2A.

[0048] In yet another aspect, the invention features crystalline form H of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at the 2-theta values ​​(°2θ) shown in Table 2.

[0049] In yet another aspect, the invention features crystalline form H of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 2-theta values ​​(°2θ) of 13.79±0.2°, 23.61±0.2°, and 27.10±0.2°. In some embodiments, the characteristic peaks shown are the highest peaks in the XRPD pattern.

[0050] In yet another aspect, the invention features crystalline form H of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at two-theta values ​​(°2θ) of 13.79±0.2°, 23.61±0.2°, 27.10±0.2°, and 27.49±0.2°. In some embodiments, the characteristic peaks shown are the highest peaks in the XRPD pattern.

[0051] In yet another aspect, the present invention provides a method for detecting 2 theta values ​​(°2θ) of 4.59±0.2°, 11.92±0.2°, 12.27±0.2°, 13.47±0.2°, 13.79±0.2°, 14.82±0.2°, 15.27±0.2°, 15.89±0.2°, 16.28±0.2°, 18.08±0.2°, 19.24±0.2°, 20.08±0.2°, 21.08±0.2°, 22.08±0.2°, 23.08±0.2°, 24.08±0.2°, 25.08±0.2°, 26.08±0.2°, 27.08±0.2°, 28.08±0.2°, 29.08±0.2°, 30.08±0.2°, 31.08±0.2°, 32.08±0.2°, 33.08±0.2°, 34.08±0.2°, 35.08±0.2°, 36.08±0.2°, 37.08±0.2°, 38.08±0.2°, 39.08±0.2°, 40.08±0.2°, 41.08±0.2°, 42.08±0.2°, 43.08±0.2°, 44.08±0.2°, 45.08±0.2°, 46.08±0.2°, 47.08±0.2°, 48.08±0.2°, 49.08±0 Crystalline form H of compound 100 is characterized as having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 0.77±0.2°, 23.61±0.2°, 24.47±0.2°, 25.11±0.2°, 26.13±0.2°, 27.10±0.2°, 27.49±0.2°, 28.42±0.2°, and 30.49±0.2°.

[0052] In yet another aspect, the invention features crystalline form H of Compound 100, characterized by a differential scanning calorimetry pattern with an extrapolated onset temperature at 258°±2° C. More specifically, the invention features crystalline form H of Compound 100, characterized by a differential scanning calorimetry pattern with extrapolated onset temperatures at 74.1°±1° C., 241.4°±1° C., and 257.0°±1° C.

[0053] In yet another aspect, the invention features crystalline Form E of Compound 100, having characteristic peaks in an X-ray powder diffraction (XRPD) pattern substantially similar to Figure 3A.

[0054] In yet another aspect, the invention features crystalline form E of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at the 2-theta values ​​(°2θ) shown in Table 3.

[0055] In yet another aspect, the invention features crystalline Form E of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at two-theta values ​​(°2θ) of 11.71±0.2°, 15.24±0.2°, 24.79±0.2°, and 26.15±0.2°. In some embodiments, the characteristic peaks shown are the highest peaks in the XRPD pattern.

[0056] In yet another aspect, the invention features crystalline Form E of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 2-theta values ​​(°2θ)=11.71±0.2°, 14.39±0.2°, 15.24±0.2°, 15.63±0.2°, 17.02±0.2°, 17.84±0.2°, 18.30±0.2°, 19.56±0.2°, 20.22±0.2°, 20.65±0.2°, 23.96±0.2°, 24.79±0.2°, and 26.15±0.2°.

[0057] In yet another aspect, the invention features crystalline Form E of Compound 100, characterized by a differential scanning calorimetry pattern with extrapolated onset temperatures at 78.5° C.±2° C. and 256.7° C.±2° C. In some embodiments, there is an additional extrapolated onset temperature at 257.9° C.±2° C.

[0058] In yet another aspect, the invention features crystalline Form G of Compound 100, having characteristic peaks in an X-ray powder diffraction (XRPD) pattern substantially similar to Figure 4A.

[0059] In yet another aspect, the invention features crystalline form G of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at the 2-theta values ​​(°2θ) shown in Table 4.

[0060] In yet another aspect, the invention features crystalline Form G of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 2-theta values ​​(°2θ) of 15.34±0.2°, 24.58±0.2°, and 25.86±0.2°. In some embodiments, the characteristic peaks shown are the highest peaks in the XRPD pattern.

[0061] In yet another aspect, the present invention provides a method for detecting 2 theta values ​​(°2θ) of 7.88±0.2°, 11.82±0.2°, 12.85±0.2°, 14.39±0.2°, 14.96±0.2°, 15.34±0.2°, 15.81±0.2°, 16.70±0.2°, 17.40±0.2°, 19.51±0.2°, 19.72±0.2°, 20. The present invention is characterized by crystalline form G of compound 100 having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 0.17±0.2°, 20.63±0.2°, 23.18±0.2°, 23.90±0.2°, 24.58±0.2°, 25.33±0.2°, 25.86±0.2°, 26.26±0.2°, and 28.61±0.2°.

[0062] In yet another aspect, the invention features crystalline form G of Compound 100, characterized by a differential scanning calorimetry pattern with extrapolated onset temperatures at 80.5°±2° C. and 257.2°±2° C. In some embodiments, there is an additional extrapolated onset temperature at 258.3°±2° C.

[0063] In yet another aspect, the invention features crystalline Form B of Compound 100, having characteristic peaks in an X-ray powder diffraction (XRPD) pattern substantially similar to Figure 5A.

[0064] In yet another aspect, the invention features crystalline Form B of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at the 2-theta values ​​(°2θ) shown in Table 5.

[0065] In yet another aspect, the invention features crystalline Form B of Compound 100 having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at two-theta values ​​(°2θ) of 4.40±0.2°, 17.48±0.2°, 17.72±0.2°, 18.46±0.2°, and 27.49±0.2°. In some embodiments, the characteristic peaks shown are the highest peaks in the XRPD pattern.

[0066] In yet another aspect, the present invention provides 2 theta values ​​(°2θ) = 4.40 ± 0.2°, 8.74 ± 0.2°, 9.13 ± 0.2°, 11.67 ± 0.2°, 12.51 ± 0.2°, 13.10 ± 0.2°, 13.64 ± 0.2°, 14.03 ± 0.2°, 16.26 ± 0.2°, 16.93 ± 0.2°, 17.48 ± 0.2°, 17. Crystalline Form B of Compound 100 is characterized as having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 72±0.2°, 18.46±0.2°, 20.51±0.2°, 21.89±0.2°, 23.97±0.2°, 24.79±0.2°, 27.49±0.2°, 27.86±0.2°, and 31.76±0.2°.

[0067] In yet another aspect, the invention features crystalline Form B of Compound 100, characterized by a differential scanning calorimetry pattern having an extrapolated onset temperature at 254.5°±2° C. In some embodiments, there is an additional extrapolated onset temperature at 256.3±2° C.

[0068] In yet another aspect, the invention features crystalline Form C of Compound 100, having characteristic peaks in an X-ray powder diffraction (XRPD) pattern substantially similar to Figure 6A.

[0069] In yet another aspect, the invention features crystalline Form C of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at the 2-theta values ​​(°2θ) shown in Table 6.

[0070] In yet another aspect, the invention features crystalline Form C of Compound 100 having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at two-theta values ​​(°2θ) of 4.42±0.2°, 8.83±0.2°, 13.27±0.2°, and 17.72±0.2°. In some embodiments, the characteristic peaks shown are the highest peaks in the XRPD pattern.

[0071] In yet another aspect, the invention features crystalline Form C of Compound 100, having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 2-theta values ​​(°2θ) of 4.42±0.2°, 8.83±0.2°, 10.52±0.2°, 13.27±0.2°, 16.58±0.2°, 16.97±0.2°, 17.72±0.2°, 21.18±0.2°, 22.21±0.2°, and 24.49±0.2°.

[0072] In yet another aspect, the invention features crystalline Form C of Compound 100, characterized by a differential scanning calorimetry pattern with extrapolated onset temperatures at 49.6° C.±2° C. and 257.9° C.±2° C. In some embodiments, there is an additional extrapolated onset temperature at 258.9° C.±2° C.

[0073] The XRPD data used herein can be collected using a D8 ADVANCE X-ray diffractometer (Bruker) equipped with a LynxEye detector. For XRPD analysis, samples were scanned from 3 to 40° (2θ) with a step time of 0.3 seconds. The tube voltage and current were 40 kV and 40 mA, respectively. The measurement error of XRPD peak positions is typically ±0.2 degrees two-theta (°2θ). Alternatively, XRPD data can be collected using a PANalytical Empyrean powder X-ray diffractometer and an X'Pert3 powder X-ray diffractometer using the following parameters:

[0074] [Table 1]

[0075] As used herein, differential scanning calorimetry (DSC) data collection can be performed using a Discovery DSC 250 (TA Instruments, US). A weighed sample is placed in a DSC pinhole pan and the weight is accurately recorded. The sample is heated at 10°C / min to the final temperature. As used herein, a DSC dataset is "substantially similar" to another DSC dataset if one or more feature values ​​in one dataset are within ±3°C of the corresponding feature value in the other dataset.

[0076] Thermogravimetric analysis (TGA) data collection used herein can be performed using a Discovery TGA 55 (TA Instruments, US). Samples can be placed in pre-tared open aluminum pans, automatically weighed, and inserted into the TGA furnace. Samples can be heated at 10°C / min to the final temperature.

[0077] Alternatively, TGA and DSC data collection can be performed using a TA Instruments TA Q500 / Q5000 / 5500 TGA and a TA Instruments TA Q200 / Q2000 / 2500 DSC, respectively, using the following parameters:

[0078] [Table 2]

[0079] In another aspect, the invention features any one of the above crystalline form embodiments that is substantially pure. As used herein, the term "substantially pure," when used with respect to a given crystalline form, refers to a crystalline form that is at least about 90% pure, meaning that the crystalline form contains no more than about 10% of other forms of Compound 100. More preferably, the term "substantially pure" refers to a crystalline form of Compound 100 that is at least about 95% pure, meaning that the crystalline form of Compound 100 contains no more than about 5% of other forms of Compound 100. Even more preferably, the term "substantially pure" refers to a crystalline form of Compound 100 that is at least about 97% pure, meaning that the crystalline form of Compound 100 contains no more than about 3% of other forms of Compound 100. As used herein, the term "about" is defined as being consistent with the understanding of one of ordinary skill in the art. In one non-limiting embodiment, the term "about" when used in reference to an amount or volume of a reagent or solvent is defined as within 10%, preferably within 5%, more preferably within 1%, and most preferably within 0.5%.

[0080] In yet another aspect, the invention features a process for preparing a composition (such as a pharmaceutical composition) containing Compound 100 using a crystalline form of the invention.

[0081] The compositions and methods of the present invention can be used to treat subjects in need of treatment. In certain embodiments, the subject is a mammal (such as a human or non-human mammal). When administered to a subject (such as a human), the composition or compound is preferably administered as a pharmaceutical composition (e.g., comprising a compound of the present invention and a pharmaceutically acceptable carrier). Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions (such as water or physiologically buffered saline) or other solvents or vehicles (such as glycols, glycerol, oils (such as olive oil), or injectable organic esters). In preferred embodiments, when such pharmaceutical compositions are intended for administration to humans, particularly those intended for invasive administration routes (i.e., routes that avoid transport or diffusion through epithelial barriers, such as injection or implantation), the aqueous solution is pyrogen-free or substantially pyrogen-free. Pharmaceutical excipients can be selected, for example, to delay drug release. The pharmaceutical composition can be included in a unit dosage form, such as a tablet, capsule (including sprinkle capsules and gelatin capsules), granule, lyophilizate for reconstitution, powder, solution, or syrup, etc. In some embodiments, the composition is a tablet or capsule.

[0082] Pharmaceutically acceptable carriers may contain physiologically acceptable agents, such as those that stabilize, improve the solubility, or promote the absorption of a compound (such as a compound of the present invention). Such physiologically acceptable agents include, for example, carbohydrates (such as glucose, sucrose, or dextran), antioxidants (such as ascorbic acid or glutathione), chelating agents, low-molecular-weight proteins, or other stabilizers or pharmaceutical additives. The choice of pharmaceutically acceptable carrier, including physiologically acceptable agents, depends, for example, on the route of administration of the composition.

[0083] The phrase "pharmaceutically acceptable" is used herein to mean that a compound, material, composition, and / or dosage form is suitable, under sound medical judgment, for use in contact with the tissues of a subject without excessive toxicity, irritation, allergic response, or other problem or complication, and is commensurate with a reasonable benefit / risk ratio.

[0084] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle (such as a liquid or solid excipient, diluent, pharmaceutical additive, solvent, or encapsulating material). Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject. Some examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars (such as lactose, glucose, and sucrose), (2) starches (such as corn starch and potato starch), (3) cellulose and its derivatives (such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate), (4) powdered tragacanth, (5) malt, (6) gelatin, (7) talc, (8) pharmaceutical additives (such as cocoa butter and suppository wax), and (9) oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil). (10) glycols (such as propylene glycol), (11) polyols (such as glycerin, sorbitol, mannitol, and polyethylene glycol), (12) esters (such as ethyl oleate and ethyl laurate), (13) agar, (14) buffers (such as magnesium hydroxide and aluminum hydroxide), (15) alginic acid, (16) pyrogen-free water, (17) isotonic saline, (18) Ringer's solution, (19) ethyl alcohol, (20) phosphate buffer, and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0085] The pharmaceutical compositions (preparations) of the present invention are preferably administered to a subject orally.

[0086] The formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy. The amount of active ingredient that may be combined with a carrier material to produce a single dosage form will vary depending on the subject being treated and the particular mode of administration. The amount of active ingredient that may be combined with a carrier material to produce a single dosage form will generally be that amount of compound that produces a therapeutic effect. Generally, this amount, expressed as a percentage of 100 percent active ingredient, will range from about 0.5 percent to about 99 percent, preferably from about 0.75 percent to about 40 percent, and most preferably from about 0.8 percent to about 12.5 percent.

[0087] Methods of preparing such formulations or compositions include the step of bringing into association a crystalline form of the present invention with the carrier(s) and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0088] To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules, and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers (such as sodium citrate or dicalcium phosphate or a solvent), and / or any of the following: (1) excipients or fillers (such as starch, lactose, sucrose, glucose, mannitol, microcrystalline cellulose, and / or silicic acid), (2) binders (such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia), (3) humectants (such as glycerol), (4) disintegrants (such as agar-agar, calcium carbonate, potato starch, or tapioca), and / or (5) disintegrants (such as sorbitol, ... starch, alginic acid, certain silicates, sodium carbonate, and cross-linked carboxymethylcellulose salts), (5) solution flow retardants (such as paraffin), (6) absorption enhancers (such as quaternary ammonium compounds), (7) wetting agents (such as cetyl alcohol and glycerol monostearate), (8) adsorbents (such as kaolin and bentonite clay), (9) lubricants (such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, and mixtures thereof), (10) complexing agents (such as modified and unmodified cyclodextrins), (11) coloring agents, (12) glidants (such as colloidal silicon dioxide), and (13) hydrophilic polymers. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets, and pills, the pharmaceutical compositions may also include buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[0089] Tablets can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surfactants, or dispersants. Molded tablets can be prepared by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine.

[0090] The selected dose level will depend on a variety of factors, including the activity of the particular compound or combination of compounds, or esters, salts, or amides thereof, used, the route of administration, the time of administration, the rate of excretion of the particular compound(s) used, the duration of treatment, other drugs, compounds, and / or materials used in combination with the particular compound(s) used, the age, sex, weight, condition, general health, and prior medical history of the subject being treated, and similar factors well known in the medical arts.

[0091] A physician or veterinarian skilled in the art can easily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, such a physician or veterinarian can establish an initial dose of the pharmaceutical composition or compound at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dose until the desired effect is achieved. A "therapeutically effective amount" refers to a concentration of the compound sufficient to induce the desired therapeutic effect. It is generally understood that the effective amount of a compound will vary depending on the subject's weight, sex, age, and medical history. Other factors that affect the effective amount may include, but are not limited to, the severity of the subject's condition, the disorder being treated, the stability of the compound, and, if desired, other types of therapeutic agents administered together with the compound of the present invention. The total dose delivered can be increased by administering the agent multiple times. Methods for determining efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison's Principles of Internal Medicine 13 ed., 1814-1882 (incorporated herein by reference)).

[0092] Generally, a suitable daily dose of an active compound used in the compositions and methods of the present invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

[0093] If desired, the effective daily dose of active compound can be administered as 1, 2, 3, 4, 5, 6 or more divided doses that are administered separately at appropriate intervals throughout the day, and this administration is optionally carried out in unit dosage form.In certain embodiments of the present invention, active compound can be administered 2 or 3 times a day.In preferred embodiments, active compound will be administered once a day.

[0094] In certain embodiments, the compounds of the present invention can be used alone or co-administered with another type of therapeutic agent. As used herein, the phrase "co-administration" refers to the administration of two or more different therapeutic compounds in any form, such that the first administered therapeutic compound is still effective in the body while the second compound is administered (e.g., the two compounds are effective in the subject at the same time, which may include the synergistic effect of the two compounds). For example, different therapeutic compounds can be administered simultaneously or sequentially in the same formulation or separate formulations. In certain embodiments, different therapeutic compounds can be administered within 1 hour, 12 hours, 24 hours, 36 hours, 48 ​​hours, 72 hours, or 1 week of each other. Therefore, subjects receiving such treatment can benefit from the combined effect of different therapeutic compounds.

[0095] In certain embodiments, co-administration of a compound of the invention with one or more additional therapeutic agent(s) results in improved efficacy compared to administration of either the compound of the invention or the one or more additional therapeutic agent(s) individually. In certain such embodiments, the co-administration results in an additive effect, where additive effect refers to the sum of the respective effects achieved by administering the compound of the invention and the one or more additional therapeutic agent(s) individually.

[0096] In certain embodiments, a process for forming a pharmaceutical composition of the present invention comprises: a. dissolving a crystalline form of the present invention (such as crystalline form A, crystalline form H, crystalline form E, crystalline form G, crystalline form B, or crystalline form C) in a solvent to form a solution; and b. preparing a pharmaceutical composition from the solution. In some aspects, preparing the pharmaceutical composition from the solution comprises spray-drying the solution and formulating the spray-dried solution into a solid dosage form. In some embodiments, the invention is directed to a pharmaceutical composition prepared by the process. In some embodiments, the crystalline form is form A. In some embodiments, the crystalline form is form H. In some embodiments, the crystalline form is form E. In some embodiments, the crystalline form is form G. In some embodiments, the crystalline form is form B. In some embodiments, the crystalline form is form C.

[0097] Any crystalline form described herein (including any crystalline form described in any aspect, embodiment, or example of this application) can be used in any of the processes of the invention described herein.

[0098] Treatment method Non-selective Ca 2+ Transient receptor potential (TRP) channels function as sensors that transmit extracellular cues to the intracellular environment in diverse cellular processes, including actin remodeling and cell migration (Greka et al., Nat Neurosci 6, 837-845, 2003; Ramsey et al., Annu Rev Physiol 68, 619-647, 2006; Montell, Pflugers Arch 451, 19-28, 2005; Clapham, Nature 426, 517-524, 2003). Dynamic reorganization of the actin cytoskeleton is a key component of spatiotemporally regulated Ca ions. 2+These changes depend on the influx of ATP (Zheng and Poo, Annu Rev Cell Dev Biol 23, 375-404, 2007; Brandman and Meyer, Science 322, 390-395, 2008; Collins and Meyer, Dev Cell 16, 160-161, 2009), and the small GTPases RhoA and Rac1 function as key modulators of these changes (Etienne-Manneville and Hall, Nature 420, 629-635, 2002; Raftopoulou and Hall, Dev Biol 265, 23-32, 2004). RhoA induces stress fiber and focal adhesion formation, while Rac1 mediates lamellipodia formation (Etienne-Manneville and Hall, Nature 420, 629-635, 2002). Transient receptor potential cation channel subfamily C member 5 (TRPC5) acts in concert with TRPC6 to regulate Ca2+ influx, actin remodeling, and cell motility in kidney podocytes and fibroblasts. TRPC5-mediated Ca 2+ TRPC6-mediated Ca2+ influx promotes RhoA activity, whereas TRPC6 channel gene silencing eliminates stress fibers, reduces punctate contacts, and leads to a motile, migratory cellular phenotype. In contrast, TRPC5 channel gene silencing rescues stress fiber formation and leads to a contractile cellular phenotype. The results described herein reveal a conserved signaling mechanism by which TRPC5 and TRPC6 channels control a tightly regulated balance of cytoskeletal dynamics through differential binding to Rac1 and RhoA.

[0099] Actin cytoskeleton Ca 2+Ca-dependent remodeling is a dynamic process that promotes cell migration (Wei et al., Nature 457, 901-905, 2009). RhoA and Rac1 function as switches involved in cytoskeletal reorganization in migrating cells (Etienne-Manneville and Hall, Nature 420, 629-635, 2002; Raftopoulou and Hall, Dev Biol 265, 23-32, 2004). Rac1 activation mediates a motile cell phenotype, while RhoA activity promotes a contractile phenotype (Etienne-Manneville and Hall, Nature 420, 629-635, 2002). 2+ Ca plays a central role in the regulation of small GTPases (Aspenstrom et al., Biochem J 377, 327-337, 2004). 2+ Spatially and temporally restricted flickering of Rac1 is concentrated near the leading edge of migrating cells (Wei et al., Nature 457, 901-905, 2009). Thus, Ca2+ microdomains coordinate local bursts of Rac1 activity as a key event at the leading edge (Gardiner et al., Curr Biol 12, 2029-2034, 2002; Machacek et al., Nature 461, 99-103, 2009). So far, the source of Ca2+ influx involved in GTPase regulation remains largely unknown. TRP (Transient Receptor Potential) channels are known to mediate the temporally and spatially restricted Ca2+ influx linked to cell migration in fibroblast and neuronal growth cones. 2+ Specifically, TRPC5 channels are known regulators of neuronal growth cone guidance1, and their activity in neurons is dependent on PI3K and Rac1 activity (Bezzerides et al., Nat Cell Biol 6, 709-720, 2004).

[0100] Podocytes are neuron-like cells derived from the metanephric mesenchyme of the kidney glomerulus and are essential for the formation of the kidney filtration apparatus (Somlo and Mundel, Nat Genet. 24, 333-335, 2000; Fukasawa et al., J Am Soc Nephrol 20, 1491-1503, 2009). Podocytes have an exquisitely elaborated repertoire of cytoskeletal adaptations to environmental cues (Somlo and Mundel, Nat Genet 24, 333-335, 2000; Garg et al., Mol Cell Biol 27, 8698-8712, 2007; Verma et al., J Clin Invest 116, 1346-1359, 2006; Verma et al., J Biol Chem 278, 20716-20723, 2003; Barletta et al., J Biol Chem 278, 19266-19271, 2003; Holzman et al., Kidney Int 56, 1481-1491, 1999; Ahola et al., Am J Pathol 155,907-913,1999;Tryggvason and Wartiovaara,N Engl J Med 354,1387-1401,2006;Schnabel and Farquhar,J Cell Biol 111,1255-1263,1990;Kurihara et al.,Proc Natl Acad Sci USA 89,7075-7079,1992). Early events in podocyte injury are characterized by dysregulation of the actin cytoskeleton (Faul et al., Trends Cell Biol 17, 428-437, 2007; Takeda et al., J Clin Invest 108, 289-301, 2001; Asanuma et al., Nat Cell Biol 8, 485-491, 2006) and Ca2+ homeostasis (Hunt et al., J Am Soc Nephrol 16, 1593-1602, 2005; Faul et al., Nat Med 14, 931-938, 2008).These changes are associated with the development of proteinuria, loss of albumin into the urinary space, and ultimately renal failure (Tryggvason and Wartiovaara, N Engl J Med 354, 1387-1401, 2006). The vasoactive hormone angiotensin II stimulates podocyte Ca2+ levels. 2+ Treatment with ATP induces Ca2+ influx, and long-term treatment results in the loss of stress fibers (Hsu et al., J Mol Med 86, 1379-1394, 2008). Although the connection between Ca2+ influx and cytoskeletal reorganization is recognized, the mechanisms by which podocytes sense and transduce extracellular cues that regulate cell shape and motility remain unclear. Mutations in the TRP canonical 6 (TRPC6) channel have been linked to podocyte injury (Winn et al., Science 308, 1801-1804, 2005; Reiser et al., Nat Genet 37, 739-744, 2005; Moller et al., J Am Soc Nephrol 18, 29-36, 2007; Hsu et al., Biochim Biophys Acta 1772, 928-936, 2007), but the specific pathways regulating this process remain largely unknown. Furthermore, TRPC6 shares close similarity with the other six members of the TRPC channel family (Ramsey et al., Annu Rev Physiol 68, 619-647, 2006; Clapham, Nature 426, 517-524, 2003). TRPC5 channels antagonize TRPC6 channel activity and control a tightly regulated balance of cytoskeletal dynamics through differential binding to different small GTPases.

[0101] Proteinuria Proteinuria is a pathological condition characterized by the presence of protein in the urine. Albuminuria is a type of proteinuria. Microalbuminuria occurs when the kidneys leak small amounts of albumin into the urine. In a properly functioning body, albumin is normally absent from the urine because it is retained in the bloodstream by the kidneys. Microalbuminuria is diagnosed based on a 24-hour urine collection (20-200 μg / min) or, more commonly, at least two elevated concentrations (30-300 mg / L). Microalbuminuria can be a precursor to diabetic nephropathy. Albumin levels higher than these values ​​are called macroalbuminuria. For example, subjects with certain diseases (e.g., diabetic nephropathy) progress from microalbuminuria to macroalbuminuria, reaching the nephropathic range (>3.5 g / 24 hours) as kidney disease progresses.

[0102] Causes of Proteinuria Proteinuria can be associated with several conditions, including focal segmental glomerulosclerosis, IgA nephropathy, diabetic nephropathy, lupus nephritis, membranoproliferative glomerulonephritis, progressive (crescentic) glomerulonephritis, and membranous glomerulonephritis.

[0103] A. Focal segmental glomerulosclerosis (FSGS) Focal segmental glomerulosclerosis (FSGS) is a disease that attacks the kidney's filtering system (glomeruli), causing severe scarring. FSGS is one of many causes of a condition known as nephrotic syndrome, which occurs when protein from the blood leaks into the urine (proteinuria).

[0104] There are very few treatments available for patients with FSGS. Many patients are treated with steroid regimens, many of which are associated with severe side effects. Some patients have been shown to respond positively to immunosuppressants as well as blood pressure medications, and these medications have been shown to reduce urinary protein levels. To date, there is no universally accepted, effective treatment or therapy, and no FDA-approved medications exist to treat FSGS. Therefore, more effective methods for reducing or inhibiting proteinuria are desirable.

[0105] B. IgA nephropathy IgA nephropathy (also known as IgA nephritis, IgAN, Berger's disease, or glomerulonephritis with pharyngitis) is a form of glomerulonephritis (inflammation of the kidney's glomeruli). IgA nephropathy is the most common form of glomerulonephritis worldwide. Primary IgA nephropathy is characterized by the deposition of IgA antibodies in the glomeruli. There are other diseases associated with glomerular IgA deposition, the most common of which is Henoch-Schönlein purpura (HSP), which is considered a systemic form of IgA nephropathy. Henoch-Schönlein purpura presents with a characteristic purpuric skin rash, arthritis, and abdominal pain and occurs more commonly in young adults (ages 16–35). HSP has a more benign prognosis than IgA nephropathy. IgA nephropathy slowly progresses to chronic renal failure over a 20-year period in 25–30% of cases.

[0106] C. Diabetic nephropathy Diabetic nephropathy, also known as Kimmelstell-Wilson syndrome and intracapillary glomerulonephritis, is a progressive kidney disease caused by angiopathy of the glomerular capillaries. It is characterized by nephrotic syndrome and diffuse glomerular sclerosis. Diabetic nephropathy results from long-standing diabetes and is the primary cause of dialysis. The earliest detectable change in the course of diabetic nephropathy is thickening of the glomeruli. At this stage, the kidneys may begin to leak more serum albumin than normal into the urine. As diabetic nephropathy progresses, an increasing number of glomeruli are destroyed by nodular glomerulosclerosis, leading to increased amounts of albumin excreted in the urine.

[0107] D. Lupus nephritis Lupus nephritis is a kidney disorder that is a complication of systemic lupus erythematosus (SLE). It occurs when antibodies and complement build up in the kidneys, causing inflammation. Lupus nephritis often causes proteinuria and can rapidly progress to kidney failure. Nitrogenous waste products build up in the bloodstream. SLE causes various damage to the internal structures of the kidneys, including interstitial nephritis. Lupus nephritis affects approximately 3 in 10,000 people.

[0108] E. Membranoproliferative glomerulonephritis I / II / III Membranoproliferative glomerulonephritis (MPN) is a type of glomerulonephritis caused by the deposition of mesangial deposits and thickening of the basement membrane in the renal glomeruli, which activates complement and damages the glomeruli. There are three types of MNPN: Type I, which is caused by immune complex deposition in the kidney and is thought to be related to the classical complement pathway; Type II, which is similar to MNPN but is thought to be related to the alternative complement pathway; and Type III, which is extremely rare and is characterized by a combination of subepithelial deposits and the typical pathology of Type I disease.

[0109] F. Progressive (crescentic) glomerulonephritis Progressive (crescentic) glomerulonephritis (PG) is a renal syndrome that, if left untreated, rapidly progresses to acute renal failure and death within several months. PG is associated with an underlying condition, such as Goodpasture's syndrome, systemic lupus erythematosus, or Wegener's granulomatosis, in 50% of cases; the remaining cases are idiopathic. Regardless of the underlying cause, PG involves significant damage to the renal glomeruli, many of which have characteristic crescent-shaped scars. Patients with PG have hematuria, proteinuria, and, occasionally, elevated blood pressure and edema. Although the clinical picture is consistent with nephrotic syndrome, the degree of proteinuria can exceed 3 g / 24 hours, the range associated with nephrotic syndrome. If the disease is untreated, it may progress to decreased urine output (oliguria) as renal function declines.

[0110] G. Membranous glomerulonephritis Membranous glomerulonephritis (MGN) is a slowly progressive kidney disease that primarily affects patients between the ages of 30 and 50, usually Caucasians. Membranous glomerulonephritis can progress to nephrotic syndrome. MGN is caused by circulating immune complexes. Current research indicates that the majority of immune complexes are formed by in situ binding of antibodies to antigens on the glomerular basement membrane. These antigens may be endogenous to the basement membrane or deposited from the systemic circulation.

[0111] H. Alport syndrome Alport syndrome is a genetic disorder that affects approximately 1 in 5,000 to 10,000 children and is characterized by glomerulonephritis, end-stage renal disease, and hearing loss. Alport syndrome can also affect the eyes, but vision is usually not affected except in later cases when changes to the lens occur. Hematuria is common. Proteinuria is one of the features that develops as kidney disease progresses.

[0112] I. Hypertensive kidney disease Hypertensive kidney disease (hypertensive nephrosclerosis (HN) or HNS) or hypertensive nephropathy (HN)) is a medical condition that refers to damage to the kidneys caused by chronic hypertension. HN is classified into two types: benign and malignant. Benign nephrosclerosis is common in people over 60 years of age, while malignant nephrosclerosis is rare, affecting 1–5% of hypertensive patients with diastolic blood pressure above 130 mmHg. Signs and symptoms of chronic kidney disease (including loss of appetite, nausea, vomiting, pruritus, drowsiness or confusion, weight loss, and an unpleasant taste in the mouth) may occur. Chronic hypertension causes damage to kidney tissue, including small blood vessels, glomeruli, renal tubules, and interstitial tissue. The tissue hardens and thickens (this is known as nephrosclerosis). Narrowing of blood vessels means that less blood is delivered to the tissues, and therefore less oxygen reaches them, resulting in tissue death (ischemia).

[0113] J. Nephrotic syndrome Nephrotic syndrome is a group of symptoms resulting from kidney damage. Nephrotic syndrome includes proteinuria, low blood albumin levels, high blood lipids, and significant swelling. Other symptoms can include weight gain, fatigue, and foamy urine. Complications can include blood clots, infections, and high blood pressure. Causes include multiple kidney diseases, such as focal segmental glomerulosclerosis, membranous nephropathy, and minimal change nephrotic syndrome. It can also occur as a complication of diabetes or lupus. The underlying mechanism typically involves damage to the kidney's glomeruli. Diagnosis is typically based on urinalysis and, occasionally, kidney biopsy. Nephrotic syndrome differs from nephritic syndrome in that red blood cells are not present in the urine. Nephrotic syndrome is characterized by massive proteinuria (more than 3.5 g per 1.73 m2 of body surface area per day, or more than 40 mg per square meter of body surface area per hour in children), hypoalbuminemia (less than 2.5 g / dL), hyperlipidemia, and edema, beginning with the face. Lipiduria (lipids in the urine) may also occur but is not required for the diagnosis of nephrotic syndrome. Hyponatremia also occurs when sodium excretion is low. Genetic forms of nephrotic syndrome are typically resistant to steroids and other immunosuppressive treatments. The goals of treatment are to control urinary protein loss and swelling, provide adequate nutrition to allow the child to grow, and prevent complications. Early and aggressive treatment is used to control the disorder.

[0114] K. Minimal change nephrotic syndrome Minimal change nephrotic syndrome (MCS), also known as minimal change glomerulopathy (MCG), or Nir disease, is a disease that affects the kidneys and causes nephrotic syndrome. Clinical signs of minimal change nephrotic syndrome include proteinuria (abnormal urinary excretion of protein, primarily albumin), edema (swelling of soft tissues as a result of fluid retention), weight gain, and hypoalbuminemia (low serum albumin). Collectively, these signs are referred to as nephrotic syndrome. The first clinical sign of minimal change nephrotic syndrome is usually edema and associated weight gain. While swelling can be mild, patients may also present with lower extremity edema, periorbital edema, and swelling in the scrotal / labial area, and in severe cases, anasarca. In elderly patients, patients may also present with acute kidney injury (20–25% of affected adults) and hypertension. Due to the disease process, patients with minimal change nephrotic syndrome are also at risk for blood clots and infections.

[0115] L.Membranous nephropathy Membranous nephropathy refers to the deposition of immune complexes on the glomerular basement membrane (GBM), accompanied by thickening of the GBM. The cause is usually unknown (idiopathic), but secondary causes include drugs, infections, autoimmune disorders, and cancer. Findings include insidious onset of edema and heavy proteinuria with benign urinary sediment, normal renal function, and normal or elevated blood pressure. Membranous nephropathy is diagnosed by kidney biopsy. Spontaneous remission is common. Treatment for patients at high risk of progression typically involves corticosteroids and cyclophosphamide or chlorambucil.

[0116] M. postinfectious glomerulonephritis Acute proliferative glomerulonephritis is damage to the glomeruli (glomerulonephritis), i.e., the small blood vessels of the kidney. It is a common complication of bacterial infection, typically skin infections caused by Streptococcus types 12, 4, and 1 (impetigo), but can also occur after streptococcal pharyngitis, also known as postinfectious or poststreptococcal glomerulonephritis. This nephritis can be a risk factor for future albuminuria. In adults, signs and symptoms of infection may still be present at the time of kidney problems, and the terms infection-associated glomerulonephritis or bacterial infection-associated glomerulonephritis are also used. Deaths from acute glomerulonephritis worldwide have decreased from 24,000 in 1990 to 19,000 in 2013. Acute proliferative glomerulonephritis (poststreptococcal glomerulonephritis) occurs when streptococci infect the kidney (usually in the throat or skin), usually three weeks after infection, allowing time for antibodies and complement proteins to be produced. The infection causes inflammation of the kidney's blood vessels, which interferes with the kidney's ability to filter urine.[citation needed] Acute proliferative glomerulonephritis is most commonly seen in children.

[0117] N. Thin basement membrane disease Thin basement membrane disease (TBMD, also known as benign familial hematuria and thin basement membrane nephropathy (TBMN)), along with IgA nephropathy, is the most common cause of asymptomatic hematuria. The only abnormal finding in this disease is thinning of the glomerular basement membrane of the kidney. Its significance lies in the fact that patients maintain normal renal function throughout their lives and have a favorable prognosis. Most patients with thin basement membrane disease have incidental microscopic hematuria detected on urinalysis. Blood pressure, renal function, and urinary protein excretion are usually normal, although a small percentage of patients have mild proteinuria (<1.5 g / day) and elevated blood pressure. The presence of frank hematuria and lumbar pain should prompt investigation for other causes, such as kidney stones or lumbar pain-hematuria syndrome. Furthermore, because there are no systemic symptoms, the presence of hearing or visual impairment should prompt investigation for hereditary nephropathies, such as Alport syndrome. Some people with TBMD are thought to be carriers of the gene that causes Alport syndrome.

[0118] O. Mesangial proliferative glomerulonephritis Mesangial proliferative glomerulonephritis is a form of glomerulonephritis that primarily involves the mesangium. There is some evidence that interleukin-10 inhibits it in animal models. [2] The World Health Organization (WHO) classifies it as type II lupus nephritis. Mesangial cells in the renal glomerulus use endocytosis to internalize and degrade circulating immunoglobulins. This normal process promotes mesangial cell proliferation and matrix deposition. Therefore, when circulating immunoglobulin concentrations are elevated (i.e., in lupus and IgA nephropathy), the number of mesangial cells and matrix within the glomerulus is expected to increase, which is a hallmark of nephritic syndromes.

[0119] P. Amyloidosis (primary) Amyloidosis is a group of diseases in which abnormal proteins known as amyloid fibrils accumulate in tissues.[4] Symptoms vary depending on the type and often vary.[2] Symptoms may include diarrhea, weight loss, fatigue, tongue enlargement, bleeding, numbness, fainting upon standing, swelling of the feet, or an enlarged spleen.[2] There are approximately 30 different types of amyloidosis, each resulting from the misfolding of a specific protein.[5] Some are hereditary, while others are acquired.[3] They are classified as localized and systemic forms.[2] The four most common types of systemic disease are light chain (AL), inflammatory (AA), dialysis (Aβ2M), hereditary, and elderly (ATTR) forms. Primary amyloidosis refers to amyloidosis without an associated clinical condition.

[0120] Q. c1q nephropathy C1q nephropathy is a rare glomerular disease characterized by characteristic mesangial C1q deposits on immunofluorescence microscopy. This nephropathy is histologically defined and poorly understood. Light microscopic features are heterogeneous and include minimal change nephrotic syndrome (MCD), focal segmental glomerulosclerosis (FSGS), and proliferative glomerulonephritis. Clinical presentations are also diverse, ranging from asymptomatic hematuria or proteinuria to frank nephritis or nephrotic syndrome in both children and adults. Elevated blood pressure and renal insufficiency at diagnosis are common findings. Optimal treatment is unclear and is usually guided by the underlying light microscopic lesion. Corticosteroids are the mainstay of treatment, with immunosuppressants reserved for steroid-resistant cases. The presence of nephrotic syndrome and FSGS appears to predict adverse outcomes in contrast to the favorable outcomes in MCD patients. (Devasahayam, et al., “C1q Nephropathy: The Unique Underrecognized Pathological Entity,” Analytical Cellular Pathology, vol. 2015, Article ID 490413, 5 pages, 2015. https: / / doi.org / 10.1155 / 2015 / 490413.)

[0121] R. Anti-GBM disease Anti-glomerular basement membrane (GBM) disease, also known as Goodpasture's disease, is a rare condition that causes inflammation of small blood vessels in the kidneys and lungs. Although anti-glomerular basement membrane (GBM) antibodies primarily attack the kidneys and lungs, systemic symptoms such as fatigue, weight loss, tiredness, fever, and chills are also common, as well as joint aches and pains. 60–80% of patients with this condition experience both pulmonary and renal abnormalities, 20–40% have renal abnormalities alone, and less than 10% have pulmonary abnormalities alone. Pulmonary symptoms usually precede renal symptoms and typically include hemoptysis, chest pain (in less than 50% of cases), cough, and shortness of breath. Renal symptoms typically include hematuria, proteinuria, unexplained swelling of the limbs or face, excessive blood urea, and high blood pressure. GPS causes abnormal production of anti-GBM antibodies by blood plasma cells. Anti-GBM antibodies attack the alveoli and glomerular basement membrane. These antibodies bind reactive epitopes to the basement membrane, activating the complement cascade and killing targeted cells. T cells are also involved. The disease is generally considered a type II hypersensitivity reaction.

[0122] Measurement of urine protein levels Urinary protein levels can be measured using methods known in the art. Until recently, accurate protein measurements required a 24-hour urine collection. In a 24-hour collection, patients urinate into a container and refrigerate it after each toilet visit. Patients are instructed to begin collecting urine after their first toilet visit in the morning. All remaining urine for the day is collected in the container. The next morning, the patient completes the collection with the first urine they urinate upon waking.

[0123] More recently, researchers have found that a single urine sample can provide the necessary information. Newer methods compare the amount of albumin in a urine sample with the amount of creatinine, a waste product formed by the breakdown of normal muscle. This measurement is called the urinary albumin-to-creatinine ratio (UACR). A urine sample containing more than 30 milligrams of albumin per gram of creatinine (30 mg / g) signals a potential problem. If the lab value exceeds 30 mg / g, another UACR test should be performed in 1 to 2 weeks. If the second test also shows high levels of protein, the patient has persistent proteinuria, a sign of declining kidney function, and should undergo additional testing to evaluate kidney function.

[0124] Tests that measure the amount of creatinine in the blood also indicate whether a person's kidneys are efficiently removing waste products. Excess creatinine in the blood is a sign of kidney damage. Doctors can use creatinine measurements to estimate how efficiently the kidneys are filtering blood. This calculation is called the estimated glomerular filtration rate (or eGFR). Chronic kidney disease is present when the eGFR is less than 60 milliliters per minute (mL / min).

[0125] TRPC5 TRPCs are a family of animal transient receptor potential cation channels. TRPC5 is a subtype of the TRPC family of mammalian transient receptor potential ion channels. Three examples of TRPC5 are found in humans (GenBank accession numbers NM_012471.2 and NP_036603.1; Gene ID 7224), mice (GenBank accession numbers NM_009428.2 and NP_033454.1; Gene ID 22067), and rats (GenBank accession numbers NM_080898.2 and NP_543174.1; Gene ID 140933).

[0126] TRPC1 TRPC1 is an ion channel located on the plasma membrane of many human and animal cell types. TRPC1 is a nonspecific cation channel, meaning that both sodium and calcium ions can pass through it. TRPC1 is thought to mediate calcium influx in response to depletion of endoplasmic reticulum calcium stores or activation of receptors coupled to the phospholipase C system. In HEK293 cells, the unit current-voltage relationship of endogenous TRPC1 channels is nearly linear, with a slope yielding a conductance of approximately 17 pS. The estimated reversal potential of TRPC1 channels is +30 mV. TRPC1 protein is widely expressed throughout the mammalian brain, and its expression pattern in the corticolimbic system is similar to that of TRPC4 and TRPC5. The highest densities of TRPC1 protein are found in the lateral septum (region of high TRPC4 expression) and the hippocampus and prefrontal cortex (regions of high TRPC5 expression).

[0127] TRPC4 TRPC4 is a member of the transient receptor potential cation channel family. This protein forms a nonselective, calcium-permeable cation channel activated by Gαi-coupled receptors, Gαq-coupled receptors, and tyrosine kinases, and plays a role in multiple processes, including endothelial permeability, vasodilation, neurotransmitter release, and cell proliferation. This nonselective cation channel, TrpC4, has been shown to be abundant in corticolimbic regions of the brain. Furthermore, TRPC4 mRNA is present in midbrain dopaminergic neurons in the ventral tegmental area and substantia nigra. Deletion of the trpc4 gene results in reduced levels of sociability in a social exploration task. These results suggest that TRPC4 may play a role in regulating social anxiety in many different disorders. TRPC4 has been shown to interact with TRPC1 and TRPC5.

[0128] Thus, the present invention provides a method for inhibiting one or more of the TRPC1 ion channel, the TRPC4 ion channel, and the TRPC5 ion channel, or a tetrameric ion channel comprising any combination of TRPC1, TRPC4, and TRPC5 ion channels, in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition of Compound 100 described herein. The "tetrameric ion channel comprising any combination of TRPC1, TRPC4, and TRPC5 ion channels" can include any combination of TRPC1, TRPC4, and TRPC5 ion channels. In some embodiments, the ion channel to be inhibited is a heterotetrameric form comprising one or more TRPC1 ion channels in combination with one or more TRPC4 and / or TRPC5 ion channels. In some embodiments, the ion channel to be inhibited is a heterotetrameric form comprising one or more TRPC1 ion channels in combination with one or more TRPC4 and / or TRPC5 ion channels. In some embodiments, the ion channel to be inhibited is a heterotetrameric form comprising one or more TRPC4 ion channels and one or more TRPC5 ion channels. The heterotetrameric form can include any combination of TRPC1, TRPC4, and TRPC5 ion channels. In some embodiments, the heterotetrameric form is TRPC1:TRPC4:TRPC4:TRPC5, TRPC1:TRPC1:TRPC5:TRPC5, TRPC4:TRPC4:TRPC5:TRPC5, or TRPC4:TRPC5:TRPC5:TRPC5.

[0129] In some embodiments, the subject in need of inhibition of an ion channel comprising a tetramer of any combination of TRPC1, TRPC4, and TRPC5 suffers from a renal disease, nephropathy associated with a disease or condition, pain, anxiety, or depression. In some embodiments, the pain is selected from neuropathic pain and visceral pain. In some embodiments, the cancer is selected from chemotherapy-resistant breast cancer, adriamycin-resistant breast cancer, chemotherapy-resistant colorectal cancer, medulloblastoma, and tumor angiogenesis.

[0130] In certain embodiments, the present invention provides a method for treating or reducing the severity or risk of developing a disease or condition selected from a renal disease, nephropathy associated with the disease or condition, pain, anxiety, or depression, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one as described herein.

[0131] In some embodiments, the disease or condition is a renal disease or a neurological disorder associated with a condition or disease selected from the following: focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, Alport syndrome, hypertensive renal disease, nephrotic syndrome, steroid-resistant nephrotic syndrome, minimal change nephrotic syndrome, membranous nephropathy, idiopathic membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), immune complex-mediated MPGN, complement-mediated MPGN, lupus nephritis, post-infectious glomerulonephritis, thin basement membrane disease, mesangial proliferative glomerulonephritis, amyloidosis (primary), c1q nephropathy, rapidly progressive GN, anti-GBM disease, C3 glomerulonephritis, hypertensive nephrosclerosis, IgA nephropathy, IgG4 nephropathy, proteinuric renal disease, microalbuminuria, macroalbuminuria Urinary kidney disease, transplant-associated FSGS, transplant-associated nephrotic syndrome, transplant-associated proteinuria, nodular glomerulonephritis, NASR disease (proliferative glomerulonephritis with monoclonal IgG deposits), polycystic kidney disease, autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), or nephropathy associated with one of the following: obesity, insulin resistance, type 2 diabetes, prediabetes, metabolic syndrome, dyslipidemia, Fabry disease, pulmonary arterial hypertension, cholestatic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), or cancer.

[0132] In certain embodiments, the neurological disorder associated with a kidney disease, or condition or disorder, is focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, Alport syndrome, hypertensive kidney disease, obesity-related nephropathy, nephrotic syndrome, steroid-resistant nephrotic syndrome, minimal change nephrotic syndrome, membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), lupus nephritis, post-infectious glomerulonephritis, thin basement membrane disease, mesangial proliferative glomerulonephritis, amyloidosis (primary), c1q nephropathy, anti-GBM disease, C3 glomerulonephritis, hypertensive nephrosclerosis, IgA nephropathy, IgG4 nephropathy, dyslipidemia associated with chronic kidney disease, nodular glomerulonephritis, NASR disease (proliferative glomerulonephritis with monoclonal IgG deposits), polycystic kidney disease, nephropathy associated with Fabry disease, or nephropathy associated with metabolic syndrome.

[0133] In some embodiments, the kidney disease is a proteinuric kidney disease. In some embodiments, the kidney disease is a microalbuminuric or macroalbuminuric kidney disease.

[0134] In some embodiments, the disease or condition to be treated is nephropathy associated with pulmonary arterial hypertension.

[0135] In some embodiments, the disease or condition to be treated is pain selected from neuropathic pain and visceral pain.

[0136] In some embodiments, the disease or condition is nephropathy associated with a cancer selected from chemotherapy-resistant breast cancer, adriamycin-resistant breast cancer, chemotherapy-resistant colorectal cancer, medulloblastoma, and tumor angiogenesis.

[0137] The present invention also provides a method for treating or reducing the risk of developing anxiety or depression or cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention (e.g., a compound of Formula I) or a pharmaceutical composition containing the compound.

[0138] In some embodiments, the disease or condition to be treated is transplant-associated FSGS, transplant-associated nephrotic syndrome, transplant-associated proteinuria, cholestatic liver disease, polycystic kidney disease, autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), obesity, insulin resistance, type II diabetes, prediabetes, metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), or nonalcoholic steatohepatitis (NASH).

[0139] In some embodiments, the neuropathy associated with a kidney disease or condition or disease to be treated is hypertensive nephropathy, metabolic syndrome-associated nephropathy, obesity-associated nephropathy, dyslipidemia-associated nephropathy, diabetic nephropathy, nephrotic syndrome, FSGS, or minimal change nephrotic syndrome.

[0140] In some embodiments, the neuropathy associated with a kidney disease or condition or disease to be treated is diabetic nephropathy, FSGS, or minimal change nephrotic syndrome.

[0141] The present invention also provides a method for treating or reducing the risk of developing anxiety or depression or cancer, comprising administering to a subject in need thereof a therapeutically effective amount of Compound 100 or a pharmaceutical composition comprising said compound.

[0142] The subject to be treated by the method of the present invention is a subject who has been diagnosed with or is at risk of developing any of the above-mentioned diseases or conditions. The method is effective for a variety of subjects, including mammals, e.g., humans, and other animals, e.g., laboratory animals, e.g., mice, rats, rabbits, or monkeys, or pets and livestock, e.g., cats, dogs, goats, sheep, pigs, cows, or horses. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. [Example]

[0143] [Table 3]

[0144] Example 1. Preparation of Crystalline Form A

[0145] Method A In a 100 mL flask equipped with a magnetic stirrer, 1.0 g of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one was suspended in 15 mL of DMSO:EtOH (2:1). The slurry was stirred at room temperature for 0.5 h to allow complete dissolution. 15 mL of EtOH:HO (1:1) was added slowly over 2.0 h. The resulting suspension was filtered, washed with 15 mL of EtOH:HO (1:1), and dried under reduced pressure (-0.1 MPa) at 50°C for 3.5 h to yield 0.83 g of a white crystalline solid, characterized as Form A.

[0146] Method B

[0147] In a 100 mL flask equipped with a magnetic stirrer, 1.0 g of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one was suspended in 15 mL of DMSO:EtOH (2:1). The slurry was stirred at room temperature for 0.5 hours to allow complete dissolution. 0.3 mL of EtOH:HO (1:1) was added, followed by 0.03 g of Form A seed crystals. The resulting mixture was stirred at room temperature for 1.5 hours. Next, while maintaining stirring, an additional 15 mL of EtOH:HO (1:1) was added slowly at room temperature (0.5 mL / hour for 1 hour, then 1 mL / hour for 1 hour, then 2 mL / hour for 1 hour, and the remaining 5 mL / hour). The resulting suspension was filtered, washed with 15 mL of EtOH:H2O (1:1), and dried under reduced pressure (-0.1 MPa) at 50°C for 3.5 hours to give 0.7 g of a white crystalline solid characterized as Form A.

[0148] The powder X-ray diffraction pattern and XRPD peaks and their relative intensities of the crystalline form thus prepared are shown in Figure 1A and Table 1, respectively. The DSC and TGA data are shown in Figure 1B.

[0149] [Table 4]

[0150] Example 2. Preparation of Compound 100 Crystalline Form H

[0151] Method A In an HPLC vial containing a stir bar, 20 mg of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one was suspended in 0.5 mL of a 1:1 (v / v) mixture of IPA / IPAc. The resulting slurry was magnetically stirred (approximately 800 rpm) at 50°C for approximately 3 days while the vial remained sealed. The slurry was cooled to room temperature, and the solid was isolated by centrifugation (10,000 rpm, 2 min) and dried at room temperature for 24 h to yield a white crystalline solid.

[0152] Method B

[0153] In a 20 mL glass vial, 1.0 g of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one was dissolved in a mixture containing 10 mL of DMSO and 5 mL of IPA by stirring at 50° C. for 1 hour. The resulting solution was filtered through a 0.45 μM pore size PTFE membrane to obtain a clear solution and placed in a 100 mL flask. After adding 2 mL of IPA, a small amount of Form H seed crystals (obtained using Method A) was added, followed by the addition of an additional 103.3 mg of Form H (obtained using Method A). After stirring at 50° C. for 10 minutes, 6 mL of IPA / HO (1:1 (v / v)) was added over 6 hours while maintaining the temperature at 50° C. The stirring was stopped and the suspension was maintained at 50° C. for an additional 1.5 hours, then cooled to 25° C. and held at this temperature for 3 hours. The slurry was then filtered and the resulting wet cake was dried under reduced pressure for 12 hours. 0.77 g of Form H (white crystalline solid) was obtained in approximately 67% yield.

[0154] Method C

[0155] In a 20 mL glass vial, 1.5 g of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one was dissolved in 10 mL of DMSO by stirring at 70° C. for 1 hour. The resulting solution was filtered through a 0.45 μM pore size PTFE membrane to obtain a clear solution, which was placed in a 100 mL flask equipped with an overhead stirrer and stirred at 300 rpm at 70° C. 0.9 mL of a 1:1 (v / v) IPA / HO mixture was added, followed by the addition of a small amount of Form H seed crystals, followed by the addition of an additional 75.3 mg of Form H and 9.1 mL of 1:1 (v / v) IPA / HO over 6 hours. After the addition of IPA / HO was completed and stirring was continued at 70°C for 1 hour, the suspension was cooled to approximately 25°C with stirring for 2 hours, and then cooled without stirring for an additional hour. The suspension was filtered, and the resulting wet cake was rinsed with 20 mL of IPA and then dried in a vacuum oven at 50°C for 12 hours. 1.28 g of Form H (white crystalline solid) was obtained in approximately 80% yield.

[0156] The powder X-ray diffraction pattern and XRPD peaks and their relative intensities of the crystalline form thus prepared are shown in Figure 2A and Table 2, respectively. The DSC data are shown in Figure 2B.

[0157] [Table 5]

[0158] Example 3. Preparation of Compound 100 Crystalline Form E Approximately 15 mg of compound 100 was suspended in 0.5 mL of DMF:HO (1:9 (v / v)) in an HPLC vial. The suspension was stirred at room temperature for 3 days, and the remaining solid was then dried under vacuum at room temperature overnight. Alternatively, approximately 15 mg of compound 100 was suspended in 0.5 mL of either DMSO:HO (1:9 (v / v)) or DMF:HO (1:1 (v / v)) to obtain crystalline form E. Yet another route to crystalline form E was via crystalline form C, as described in Example 7.

[0159] The powder X-ray diffraction pattern and XRPD peaks and their relative intensities of the crystalline form thus prepared are shown in Figure 3A and Table 3, respectively. The DSC and TGA data are shown in Figure 3B.

[0160] [Table 6]

[0161] Crystalline Form E was also tested for stability at different relative humidities over a period of 3 to 14 days, with the results shown in Table 3.1 below.

[0162] [Table 7] The appearance of Form F after 14 days of storage of Form E at 30% relative humidity indicated that Form E is unstable at such low relative humidity.

[0163] Example 4. Preparation of Compound 100 Crystalline Form G Crystal form G is a w Form G can be obtained by slurrying Compound 100 in several solvent systems where the .DELTA..times ...

[0164] The powder X-ray diffraction pattern and XRPD peaks and their relative intensities of the crystalline form thus prepared are shown in Figure 4A and Table 4, respectively. The DSC and TGA data are shown in Figure 4B.

[0165] [Table 8]

[0166] Example 5. Preparation of Compound 100 Crystalline Form B Crystalline Form B was obtained by heating Compound 100 to 244°C under N2 protection and then cooling to room temperature.

[0167] Alternatively, crystalline form B was obtained by suspending approximately 30 mg of compound 100 in 1.5 mL of a 2:1 (v / v) THF:heptane mixture at room temperature to form a slurry, and the resulting wet cake was dried overnight to obtain crystalline form B.

[0168] The powder X-ray diffraction pattern and XRPD peaks and their relative intensities of the crystalline form thus prepared are shown in Figure 5A and Table 5, respectively. The DSC and TGA data are shown in Figure 5B.

[0169] [Table 9]

[0170] Example 6. Preparation of Compound 100 Crystalline Form C Crystalline Form C was prepared by dissolving Compound 100 in 1,4-dioxane, and then adding H2O, a poor solvent, to the solution to precipitate Crystalline Form C.

[0171] Crystalline Form C was also prepared by the following anti-solvent crystallization procedure: Approximately 600 mg of Compound 100 Crystalline Form A was dissolved in 70 mL of THF at room temperature. To this solution, 30 mL of heptane was added to precipitate the material. The insoluble material was isolated as a wet cake and dried overnight to obtain Crystalline Form C.

[0172] Once isolated, Form C crystals can be used as seeds in the following process to prepare additional crystalline Form C. 1000 mg of Compound 100 was suspended in 21 mL of a 2:1 (v / v) THF:HO mixture at room temperature, to which 3% (w / v) Form C crystals were added. These components were mixed together overnight to form a slurry (mixing was performed mechanically or with a magnetic stir bar). The resulting wet cake was dried to obtain crystalline Form C.

[0173] The powder X-ray diffraction pattern and XRPD peaks and their relative intensities of the crystalline form thus prepared are shown in Figure 6A and Table 6, respectively. The DSC and TGA data are shown in Figure 6B.

[0174] [Table 10]

[0175] Example 7. Use of crystalline form C to prepare crystalline form E Magnetic stirring (using a magnetic stir bar) for 24 hours without the addition of any seed crystals converted wet crystalline form C (e.g., wet cake before drying from one of the above-mentioned form C preparations) to crystalline form E. Similarly, mechanical stirring (using a shaker) for 24 to 72 hours also converted wet crystalline form C (seeded with 1% crystalline form E) to form E. However, even after 3 days of stirring, XRPD analysis revealed that 5% of the material remained as form C. Magnetic stirring appeared to favorably convert form C to form E compared to mechanical stirring. Without being bound by theory, the inventors believe that magnetic stirring enhances the conversion efficiency of form C to form E by affecting the morphology of the material. Therefore, it is possible that grinding form C to reduce its crystal size prior to stirring can enhance the conversion of form C to form E.

[0176] The foregoing description of the invention provides illustration and description, but is not intended to be exhaustive or to limit the invention to the precise form disclosed. Modifications and variations are possible in light of the above teachings or can be acquired from practice of the invention. Accordingly, the scope of the invention is defined by the claims and their equivalents.

Claims

1. a. Form A (characterized by powder X-ray diffraction peaks located at 2Θ angle = 4.43 ± 0.2°, 11.69 ± 0.2°, 17.75 ± 0.2°, and 27.58 ± 0.2°, wherein said characterized peak is the highest peak observed); b. Form E (characterized by powder X-ray diffraction peaks located at 2Θ angle = 11.71 ± 0.2°, 15.24 ± 0.2°, 24.79 ± 0.2°, and 26.15 ± 0.2°, wherein said characterized peak is the highest peak observed); c. Form G (characterized by powder X-ray diffraction peaks located at 2Θ angle=15.34±0.2°, 24.58±0.2°, and 25.86±0.2°, wherein the characterized peak is the highest peak observed); d. Form H (characterized by powder X-ray diffraction peaks located at 2Θ angle = 13.79 ± 0.2°, 23.61 ± 0.2°, 27.10 ± 0.2°, and 27.49 ± 0.2°, wherein the characterized peak is the highest peak observed); e. Form B (characterized by powder X-ray diffraction peaks located at 2Θ angles of 4.40±0.2°, 17.48±0.2°, 17.72±0.2°, 18.46±0.2°, and 27.49±0.2°, wherein the characterized peak is the highest peak observed); and f. Form C (characterized by powder X-ray diffraction peaks located at 2Θ angle = 4.42 ± 0.2°, 8.83 ± 0.2°, 13.27 ± 0.2°, and 17.72 ± 0.2°, wherein the characterized peak is the highest peak observed). A crystalline form of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one selected from

2. The crystalline form A of claim 1.

3. 3. The crystalline form A of claim 2, characterized by powder X-ray diffraction peaks located at 2Θ angle=4.43±0.2°, 8.80±0.2°, 9.17±0.2°, 11.69±0.2°, 12.27±0.2°, 13.28±0.2°, 14.24±0.2°, 14.67±0.2°, 15.96±0.2°, 16.93±0.2°, 17.75±0.2°, 19.64±0.2°, 20.98±0.2°, 22.23±0.2°, 22.71±0.2°, 24.19±0.2°, 25.55±0.2°, 27.58±0.2°, 27.95±0.2°, and 30.32±0.2°.

4. 3. The crystalline form A of claim 2, characterized by a powder X-ray diffraction pattern substantially similar to that of FIG. 1A.

5. 5. Crystalline form A according to any one of claims 1 to 4, further characterized by a differential scanning calorimetry pattern having an extrapolated onset temperature between 237±2°C and 256±2°C.

6. 6. The crystalline form A of claim 5, characterized by a differential scanning calorimetry pattern with extrapolated onset temperatures at 236.4±1°C, 243.5±1°C, and 256.3±1°C.

7. The crystalline form H of claim 1.

8. 8. The crystalline form H of claim 7, characterized by powder X-ray diffraction peaks located at 2Θ angle=4.59±0.2°, 11.92±0.2°, 12.27±0.2°, 13.47±0.2°, 13.79±0.2°, 14.82±0.2°, 15.27±0.2°, 15.89±0.2°, 16.28±0.2°, 18.08±0.2°, 19.24±0.2°, 20.77±0.2°, 23.61±0.2°, 24.47±0.2°, 25.11±0.2°, 26.13±0.2°, 27.10±0.2°, 27.49±0.2°, 28.42±0.2°, and 30.49±0.2°.

9. 8. Crystalline form H of claim 7, characterized by a powder X-ray diffraction pattern substantially similar to FIG. 2A.

10. 10. Crystalline form H of any one of claims 7 to 9, further characterized by a differential scanning calorimetry pattern having an extrapolated onset temperature at 258°±2°C.

11. 11. The crystalline form H of claim 10, further characterized by a differential scanning calorimetry pattern with additional extrapolated onset temperatures of 74.1°C ± 1°C, 241.4°C ± 1°C, and 257.0°C ± 1°C.

12. The crystalline form E of claim 1.

13. 13. The crystalline form E of claim 12, characterized by powder X-ray diffraction peaks located at 2Θ angle=11.71±0.2°, 14.39±0.2°, 15.24±0.2°, 15.63±0.2°, 17.02±0.2°, 17.84±0.2°, 18.30±0.2°, 19.56±0.2°, 20.22±0.2°, 20.65±0.2°, 23.96±0.2°, 24.79±0.2°, and 26.15±0.2°.

14. 13. The crystalline form E of claim 12, characterized by a powder X-ray diffraction pattern substantially similar to that of FIG. 3A.

15. 15. Crystalline form E of any one of claims 12 to 14, further characterized by a differential scanning calorimetry pattern with extrapolated onset temperatures at 78.5°±2°C and 256.7°±2°C.

16. 16. The crystalline form E of claim 15, further characterized by a differential scanning calorimetry pattern having an additional extrapolated onset temperature of 257.9°C ± 2°C.

17. The crystalline form G according to claim 1.

18. 18. The crystalline form G of claim 17, characterized by powder X-ray diffraction peaks located at 2Θ angle=7.88±0.2°, 11.82±0.2°, 12.85±0.2°, 14.39±0.2°, 14.96±0.2°, 15.34±0.2°, 15.81±0.2°, 16.70±0.2°, 17.40±0.2°, 19.51±0.2°, 19.72±0.2°, 20.17±0.2°, 20.63±0.2°, 23.18±0.2°, 23.90±0.2°, 24.58±0.2°, 25.33±0.2°, 25.86±0.2°, 26.26±0.2°, and 28.61±0.2°.

19. 19. Crystalline form G of claim 18, characterized by a powder X-ray diffraction pattern substantially similar to Figure 4A.

20. 20. Crystalline form G according to any one of claims 17 to 19, further characterized by a differential scanning calorimetry pattern with extrapolated onset temperatures at 80.5°±2°C and 257.2°±2°C.

21. 21. The crystalline form G of claim 20, further characterized by a differential scanning calorimetry pattern having an additional extrapolated onset temperature of 258.3°C ± 2°C.

22. A pharmaceutical composition comprising crystalline form A according to any one of claims 2 to 6 and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising crystalline form H according to any one of claims 7 to 11 and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising crystalline form E according to any one of claims 12 to 16 and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition comprising crystalline form G according to any one of claims 17 to 21 and a pharmaceutically acceptable carrier.

26. A method for inhibiting one or more of the TRPC1 ion channel, the TRPC4 ion channel, and the TRPC5 ion channel, or an ion channel constituting a tetramer of any combination of TRPC1, TRPC4, and TRPC5, in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition according to any one of claims 22 to 25.

27. 26. A method of treating a kidney disease or nephropathy associated with a disease or condition, said method comprising administering to a subject in need thereof the pharmaceutical composition of any one of claims 22-25.

28. The kidney disease or nephropathy associated with the disease or condition is selected from the group consisting of focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, Alport syndrome, hypertensive kidney disease, nephrotic syndrome, steroid-resistant nephrotic syndrome, minimal change nephrotic syndrome, membranous nephropathy, idiopathic membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), immune complex-mediated MPGN, complement-mediated MPGN, lupus nephritis, post-infectious glomerulonephritis, thin basement membrane disease, mesangial proliferative glomerulonephritis, amyloidosis (primary), c1q nephropathy, rapidly progressive GN, anti-GBM disease, C3 glomerulonephritis, hypertensive nephrosclerosis, IgA nephropathy, IgG4 nephropathy, proteinuric kidney disease, microalbuminuria, mast cell carcinoma, leukemia ...

28. The method of claim 27, wherein the nephropathy is chloroalbuminuric kidney disease, transplant-associated FSGS, transplant-associated nephrotic syndrome, transplant-associated proteinuria, nodular glomerulonephritis, NASR disease (proliferative glomerulonephritis with monoclonal IgG deposition), polycystic kidney disease, autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), or nephropathy associated with any one of obesity, insulin resistance, type II diabetes, prediabetes, metabolic syndrome, dyslipidemia, pulmonary arterial hypertension, cancer, cholestatic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), or Fabry disease.

29. 29. The method of claim 28, wherein the renal disease, or nephropathy associated with the disease or condition, is renal complications due to focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, Alport syndrome, hypertensive kidney disease, obesity-related nephropathy, nephrotic syndrome, steroid-resistant nephrotic syndrome, minimal change nephrotic syndrome, membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), lupus nephritis, post-infectious glomerulonephritis, thin basement membrane disease, mesangial proliferative glomerulonephritis, amyloidosis (primary), c1q nephropathy, anti-GBM disease, C3 glomerulonephritis, hypertensive nephrosclerosis, IgA nephropathy, IgG4 nephropathy, dyslipidemia-associated nephropathy, nodular glomerulonephritis, NASR disease (proliferative glomerulonephritis with monoclonal IgG deposits), polycystic kidney disease, or Fabry disease.

30. 30. The method of claim 29, wherein the renal disease is hypertensive nephropathy, metabolic syndrome-associated nephropathy, obesity-associated nephropathy, dyslipidemia-associated nephropathy, diabetic nephropathy, nephrotic syndrome, FSGS, or minimal change nephrotic syndrome.

31. 31. The method of claim 30, wherein the kidney disease is diabetic nephropathy, FSGS, or minimal change nephrotic syndrome.

32. 26. A method for treating pain, anxiety, or depression, said method comprising administering to a subject in need thereof the pharmaceutical composition of any one of claims 22 to 25.

33. A method for preparing crystalline form A according to any one of claims 2 to 6, said method comprising: a. dissolving an amount of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in an amount of DMSO:ethanol (2:1 (v / v)) at room temperature to form a supersaturated solution; b. A sufficient amount of ethanol to precipitate the 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one:H ２ adding O (1:1 (v / v)) to the solution of step a; c. isolating the precipitated material resulting from step b to obtain said crystalline form A; The method comprising:

34. A method for preparing crystalline form A according to any one of claims 2 to 6, said method comprising: a. dissolving an amount of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in an amount of DMSO:ethanol (2:1 (v / v)) at room temperature to form a supersaturated solution; b. To the solution of step a, add an amount of ethanol:H ２ O (1:1 (v / v)) and seed crystals of crystalline form A to precipitate the 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one; c. isolating the precipitated material resulting from step b to obtain said crystalline form A; The method comprising:

35. 1. A method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, said method comprising combining a sample of crystalline Form A with a pharmaceutically acceptable excipient.

36. 1. A method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, said method comprising: a. dissolving crystalline form A in a solvent to form a solution; b. preparing the pharmaceutical composition from the solution; The method comprising:

37. 37. The method of claim 36, wherein the preparing the pharmaceutical composition from the solution comprises spray drying the solution and formulating the spray-dried solution into a solid dosage form.

38. A pharmaceutical composition prepared by the method of any one of claims 35 to 37.

39. A method for preparing crystalline form H according to any one of claims 7 to 11, said method comprising: a. suspending 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in isopropyl alcohol:isopropyl acetate (1:1 (v / v)); b. heating the suspension of step a to a temperature of 45°C to 55°C with stirring for at least 24 hours; c. isolating the insoluble material resulting from step b to obtain said crystalline form H; The method comprising:

40. A method for preparing crystalline form H according to any one of claims 7 to 11, said method comprising: a. dissolving 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in DMSO:isopropyl alcohol (2:1 (v / v)) at a temperature of 45°C to 55°C; b. filtering the solution from step a through a PTFE membrane with a pore size of 0.45 microns; c. adding (i) isopropyl alcohol in an amount of 30-50% of the amount of isopropyl alcohol used in step a, and (ii) crystalline form H to the filtrate obtained from step b, and stirring at a temperature of 45°C to 55°C for at least 5 minutes; d. Add isopropyl alcohol:H 2 O to the solution resulting from step c for at least 4 hours with stirring while maintaining the temperature at 45°C to 55°C. ２ 2. Adding 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one (1:1 (v / v)) to obtain a suspension of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, wherein the amount of isopropyl alcohol added in steps c and d is approximately equal to the amount of isopropyl alcohol added in step a; e. Maintaining the suspension from step d at a temperature of 45°C to 55°C without stirring for at least 2 hours; f. isolating the precipitated material resulting from step e to obtain said crystalline form H; The method comprising:

41. A method for preparing crystalline form H according to any one of claims 7 to 11, said method comprising: a. dissolving 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one in DMSO at a temperature of 65° C. to 75° C.; b. filtering the solution from step a through a PTFE membrane with a pore size of 0.45 microns; c. To the filtrate obtained from step b, (i) add an amount of isopropyl alcohol:H 2 O that is about 10% of the volume of DMSO used in step A. ２ O (1:1 (v / v)), and (ii) crystalline form H; d. Add an additional amount of isopropyl alcohol:H 2 O to the filtrate from step c with stirring over a period of at least 5 hours while maintaining the temperature at 65°C to 75°C. ２ 2H-one (1:1 (v / v)) to obtain a suspension of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, wherein the total volume of isopropyl alcohol added in steps c and d is about half the volume of DMSO used in step a; e. Cooling the suspension of step d to room temperature while stirring for at least 2 hours; f. maintaining the suspension of step e at room temperature without stirring for at least an additional 45 minutes; g. isolating the precipitated material resulting from step f to obtain said crystalline form H; The method comprising:

42. 1. A method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, said method comprising combining a sample of crystalline form H with a pharmaceutically acceptable excipient.

43. 1. A method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, said method comprising: a. dissolving crystalline form H in a solvent to form a solution; b. preparing the pharmaceutical composition from the solution; The method comprising:

44. 44. The method of claim 43, wherein said preparing said pharmaceutical composition from said solution comprises spray drying said solution and formulating said spray dried solution into a solid dosage form.

45. A pharmaceutical composition prepared by the method of any one of claims 42 to 44.

46. A method for forming crystalline form E according to any one of claims 12 to 16, said method comprising: a. 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one was dissolved in DMF / H at room temperature. ２ 0 (1:9 (v / v)) to form a slurry; b. vacuum drying the suspension; The method comprising:

47. 1. A method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, said method comprising combining a sample of crystalline form E with a pharmaceutically acceptable excipient.

48. 1. A method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, said method comprising: a. dissolving crystalline form E in a solvent to form a solution; b. preparing the pharmaceutical composition from the solution; The method comprising:

49. 49. The method of claim 48, wherein the preparing the pharmaceutical composition from the solution comprises spray drying the solution and formulating the spray-dried solution into a solid dosage form.

50. A pharmaceutical composition prepared by the method of any one of claims 47 to 49.

51. A method for forming crystalline form G according to any one of claims 17 to 21, said method comprising: a. 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, ｗ suspending the compound in a solvent having a viscosity of 0.8 or more at room temperature to form a slurry; b. vacuum drying the suspension; The method comprising:

52. 51. The method of claim 50, wherein the solvent is a 1:1 (v / v) mixture of acetonitrile and water.

53. 1. A method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, said method comprising combining a sample of crystalline form G with a pharmaceutically acceptable excipient.

54. 1. A method for preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, said method comprising: a. dissolving crystalline form G in a solvent to form a solution; b. preparing the pharmaceutical composition from the solution; The method comprising:

55. 55. The method of claim 54, wherein the preparing the pharmaceutical composition from the solution comprises spray drying the solution and formulating the spray-dried solution into a solid dosage form.

56. A pharmaceutical composition prepared by the method of any one of claims 53 to 55.

57. 1. A method for inhibiting a heterotetrameric form comprising one or more TRPC1 ion channels in combination with one or more TRPC4 and / or TRPC5 ion channels in a subject in need thereof, said method comprising administering to said subject an effective amount of a pharmaceutical composition according to any one of claims 22 to 25, 38, 45, 50, or 56.

58. A method for inhibiting a heterotetrameric form comprising one or more TRPC4 ion channels and one or more TRPC5 ion channels in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition according to any one of claims 22 to 25, 38, 45, 50, or 56.

59. The subject has a kidney disease (focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, Alport syndrome, hypertensive kidney disease, nephrotic syndrome, steroid-resistant nephrotic syndrome, minimal change nephrotic syndrome, membranous nephropathy, idiopathic membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), immune complex-mediated MPGN, complement-mediated MPGN, lupus nephritis, post-infectious glomerulonephritis, thin basement membrane disease, mesangial proliferative glomerulonephritis, amyloidosis (primary), c1q nephropathy, rapidly progressive GN, anti-GBM disease, C3 glomerulonephritis, hypertensive nephrosclerosis, IgA nephropathy, IgG4 nephropathy, proteinuric kidney disease, microalbuminuria, macroalbuminuric kidney disease, transplant-associated FSGS, transplant-associated nephrotic syndrome).

59. The method of any one of claims 57-58, wherein the patient is suffering from a condition such as urinary tract infection, kidney disease, transplant-associated proteinuria, nodular glomerulonephritis, NASR disease (proliferative glomerulonephritis with monoclonal IgG deposition), polycystic kidney disease, autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), or nephropathy associated with any one of obesity, insulin resistance, type II diabetes, prediabetes, metabolic syndrome, dyslipidemia, pulmonary arterial hypertension, cancer, cholestatic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), or Fabry disease), pain (such as neuropathic pain or visceral pain), anxiety, or depression.

Images